Presenter disclosures for Randall Reves: no conflicts to report
|
|
- Cody Wilkerson
- 7 years ago
- Views:
Transcription
1 Evaluation of Interferon-γ Release Assays in the Diagnosis of Latent TB Infection in U.S. Healthcare Workers: Update on TBESC Task Order 8 National Tuberculosis Conference 20 Randall Reves, MD, MSc On behalf of the CDC TB Epidemiological Studies Consortium & the TO 8 Protocol Team Presenter disclosures for Randall Reves: no conflicts to report No personal financial relationships with the commercial interests relevant to this presentation Denver Health and Hospitals has received funding from the Centers for Disease Control, Division of Tuberculosis Elimination for the conduct of this research Background LTBI diagnosis and treatment are important components of U.S. TB control HCWs are an important group for targeted testing and treatment (~4 million/year) QuantiFERON -TB Gold In-Tube ( QFT ) and T-SPOT.TB ( T-SPOT ) are FDAapproved Require only client-provider interaction Not affected by BCG Limited longitudinal data on use of these tests in HCWs undergoing periodic testing
2 Objectives To evaluate performance characteristics of QFT and T-SPOT compared with TST for detecting LTBI in HCWs undergoing routine screening Test result stability over time (i.e. conversion, reversion) Reproducibility Test, re-test repeatability Estimated sensitivity and specificity % of failed tests Impact of TST on IGRA results To determine costs, cost-effectiveness To determine and compare acceptability of tests among participants Design and Population Longitudinal study HCWs undergoing routine LTBI testing TST- positive HCW recruited to participate 4 sites: Denver, Houston, Baltimore, NYC Inclusion: 8 yrs; informed consent; undergoing routine screening Exclusion: Current or prior active TB; TST within 6 months prior to enrollment Target sample size 2500 with baseline tests Intervention Interview QFT T-SPOT TST Consent 2 nd step TST 0 Month 6 Month 2 Month 8 2
3 Intervention Interview QFT T-SPOT TST Consent 2 nd step TST repeatability reproducibility 0 Month 6 Month 2 Month 8 Testing Methods TST Mantoux with Tubersol Administered, interpreted by study-trained personnel QuantiFERON -TB Gold In-Tube ( QFT ) Cellestis, Inc: package insert Performed, interpreted by trained technologists T-SPOT.TB ( T-SPOT ) Oxford Immunotec, Ltd: package insert Performed, interpreted by trained technologists Test kits purchased from the companies No financial support or donations from companies Technical representatives from each company assisted in training study laboratory technologists Study status Enrollment completed, follow-up ended, data editing largely done This presentation: Baseline results for 2504 participants Analysis stratified for enrollment: Required 2-step entry no TST in > 3 mo. Annual follow-up after > 2 prior TSTs Prior + TST Describe conversion/reversion for Impact of TST on IGRAs Reproducibility, Repeatability Follow-up with TST & IGRAs at 6 months 3
4 T S T :. ) S t e p 2. ) 5 3 A n n u a l F o l l o w - u p B Enrollment a by TST and LTBI History s e l i n e E n r o 232 (9.6%) Prior (+) TST and/or prior LTBI Treatment Enrollment by entry criteria: variation by site Category Den NY MD TX Total Prior Positive Two-Step Eligible Annual Follow-up Total Demographics (n= 2504) Prior + n=272 2-step n=74 Annual n=53 Total n=2504 Age (median, range) 39.7, , , , 22.2 Foreign-born 6 (50.0) 97 (3.) 25 (4.0) 428 (7.) US-B non-hisp. W 62 (26.7) 380 (5.3) 786 (5.3) 228 (49.0) US-B Hispanic 6 (6.9) 97 (3.) 233 (5.2) 346 (3.8) US-B Black 29 (2.5) 27 (7.) 225 (4.7) 38 (5.2) US-B Other 9 (3.9) 40 (5.4) 72 (4.7) 2 (4.8) HIV+ 3 (.3) 3 (0.4) 4 (0.3) 0 (0.4) Diabetes 2 (5.2) 2 (2.8) 5 (3.3) 84 (3.4) Other Immunodef. 3 (.3) 2 (2.8) 70 (4.6) 94 (3.8) 4
5 Baseline TST results: all participants Negative Positive Total Nativity & race/ethnicity N % N % N % Foreign-born % % % US-born Black/African American % % % US-born Hispanic % 4 4.0% % US-born White, % 23.9%, % US-born Other % 9 7.4% 2 4.8% Total 2, % % 2,504 00% Baseline Results for Routine Group: 2-step & Annual Follow-up (n = 2272) TST QFT T-SPOT Positive 4 (.8) 85 (3.7)* 4 (5.0)* Negative 223 (98.2) 248 (94.5) 958 (86.2) Borderline 68 (3.0) Indeterminate / Fail 39 (.7) 32 (5.8) * p < compared to the TST NOTE: Borderline T-Spots categorized as neg. for remaining slides. Baseline prior + TST: 00 F-born (5, 6.5% excluded indet./failed) TST QFT T-SPOT N % Pos Pos Pos % Pos Pos Neg 0.5% Pos Neg Pos 2 0.9% Pos Neg Neg % Neg Pos Pos 9 4.% Neg Pos Neg 7 3.2% Neg Neg Pos 9 4.% Neg Neg Neg % Total 27 00% 5
6 Baseline 2-step TST: 97 F-born (47, 6.3% excluded, indet./failed) TST QFT T-SPOT N % Pos Pos Pos 7.0% Pos Pos Neg 2 0.3% Pos Neg Neg 2 3.0% Neg Pos Pos 8.2% Neg Pos Neg 6 2.3% Neg Neg Pos % Neg Neg Neg % Total % Baseline Annual follow-up: 25 F-born (5, 6.5% excluded indet./failed) TST QFT T-SPOT N % Pos Pos Pos 8 0.6% Pos Neg Neg 2 0.% Neg Pos Pos 2 0.9% Neg Pos Neg 27.9% Neg Neg Pos % Neg Neg Neg % Total 4 00% Summary of baseline results Prior + N=27 2-step N=694 Annual N=4 TST % % 0 0.7% QFT % % % Tspot % 49 7.% % All % 7.0% 8 0.6% 6
7 Prior + TST group, Baseline Negative or Positive: 6 month Follow-up Conversion Reversion TST 0 / 90 (.) 4 / 33 (42.4) QFT 0 / 64 (6.) 7 / 53 (3.2) T-SPOT 3 / 6 (8.) 0 / 49 (20.4) Conversion = (-) baseline (+) 6 month; TST + at > 0 mm Reversion = (+) baseline (-) 6month 2-step TST, Baseline Negative or Positive: 6 month Follow-up Conversion Reversion TST / 64 (0.2) / 9 (57.9) QFT 26 / 648 (4.0) 3 / 30 (43.3) T-SPOT 32 / 604 (5.3) 25 / 43 (58.) Conversion = (-) baseline (+) 6 month Reversion = (+) baseline (-) 6month Annual f/u TST, Baseline Negative or Positive: 6 month Follow-up Conversion Reversion TST 5 / 337 (0.4) / 4 (25.0) QFT 4 / 36 (3.) 26 / 46 (56.5) T-SPOT 40 / 24 (3.2) 29 / 6 (47.5) Conversion = (-) baseline (+) 6 month Reversion = (+) baseline (-) 6month 7
8 IGRA Conversion at 2 weeks or Less Sub-study Impact TST baseline -3 wks later QFT Conversion (+)TST 0/60 (6.7) (-)TST 3/75 (4.0) T-Spot Conversions 9/60 (5.0) 5/75 (6.7) Reproducibility same phlebotomy at 6 mo. (+)TST /46 (2.2) (-)TST 4/53 (2.6) 4/46 (8.7) 3/53 (2.0) Repeatability done 2 week before 6 mo. (+)TST /44 (2.3) (-)TST 5/52 (3.3) 3/44 (6.8) 6/52 (3.9) Conversion = (-) initial (+) repeat Conclusions (): In this study of 2500 HCW in 4 US institutions Risk for TB infection appears quite low TST-conversion < 0.5 % at 6 months after 2-step testing for new staff even without recommended definition of 0 mm increase to > 0 mm Reversion of positive baseline results to negative at 6 month follow-up are common with TST and both IGRA significance uncertain but to be analyzed in follow-up at 2 and 8 months Major strength of study use of both IGRA & TST provides data to suggest that false-positives explain many of TST and IGRA results - as expected in testing low-risk populations Conclusions (2): For both IGRA compared to Mantoux TST Positive results with are higher in annual routinely testing and 4- to 5-fold higher for HCW in annual f/up Conversion rates are at least 2-4% even done the same day Lack of agreement between IGRA & TST suggest random error in both tests rather than poor TST sensitivity The protocol team is performing variability analysis, examining cut-off values and strategies of repeat assay (for QFT) and repeat testing to identify false-positive results. These findings have application to other lowprevalence populations e. g. expanding contact investigation, students traveling in high-burden settings 8
9 Thank you CDC: Paul Weinfurter, Denise Garrett, Grace Thiongo Denver: Charles Daley, Robert Belknap, Matt Parker, Randall Reves, Kirsten Wall Houston: Ed Graviss, Larry Teeter Baltimore: Wendy Cronin, Elizabeth Munk, Jonathan Golub NYC: Daniel Brodie, Joyce Thomas, Yael Hirsch-Moverman 9
Guidelines for TB Blood Testing. Minnesota Department of Health TB Prevention and Control Program June 2011
Guidelines for TB Blood Testing Minnesota Department of Health TB Prevention and Control Program June 2011 Outline Interferon-Gamma Release Assays aka TB blood tests 1. What are they? 2. What are the current
More informationInterferon-gamma Release Assays: the Good, the Bad, and the Ugly
Interferon-gamma Release Assays: the Good, the Bad, and the Ugly Susan E. Dorman, MD Center for TB Research Johns Hopkins University School of Medicine Maryland Center for Tuberculosis Control and Prevention
More informationWhat is an IGRA? What is an IGRA? Are they available here? How do I use them? Learning Objectives
What is an IGRA? Are they available here? How do I use them? Debbie Staley, RN, MPH TB Nurse Consultant VDH Division of Disease Prevention TB Control Program Learning Objectives Participants will be able
More informationCDC TB Testing Guidelines and Recent Literature Update
Pocket Guide QuantiFERON -TB Gold CDC TB Testing Guidelines and Recent Literature Update Using IGRAs for TB screening in your patients June 2010 A full copy of the US Centers for Disease Control and Prevention
More informationLisa Y. Armitige, MD, PhD has the following disclosures to make:
Interferon Gamma Release Assays (IGRAs) Lisa Y. Armitige, MD, PhD May 13, 2015 TB for Pulmonologist Phoenix, AZ March 13, 2015 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following
More informationSanta Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014. Frequently Asked Questions
Frequently Asked Questions A child has history of BCG vaccination, should they have TST or IGRA? According to the American Academy of Pediatrics Red Book (2012), Interferon Gamma Release Assay (IGRA) is
More informationDIVISION of SUBSTANCE ABUSE SERVICES. Tuberculosis Control Guidelines for Alcohol and Drug Abuse Treatment Programs
DIVISION of SUBSTANCE ABUSE SERVICES Tuberculosis Control Guidelines for Alcohol and Drug Abuse Treatment Programs 1. Purpose: This policy provides guidance and instruction to identify and prevent tuberculosis
More informationWhat You Need to Know About Collecting QuantiFERON (QFT) TB Gold In-Tube Samples
What You Need to Know About Collecting QuantiFERON (QFT) TB Gold In-Tube Samples I. What is QuantiFERON (QFT) TB Gold In-Tube? II. III. QFT is an interferon-gamma release assay (IGRA). QFT is a blood test.
More informationNevada State Health Division Technical Bulletin
Nevada State Health Division Technical Bulletin Topic: Using QuantiFERON and Tuberculin Skin Test to Screen for TB Section/Program/Contact: Bureau of Community Health / Tuberculosis Program / Susanne Paulson,
More informationDRAFT FOR CONSULTATION
Interferon Gamma Release Assay (IGRA) testing for tuberculosis (TB) - Questions & Answers (Q&As) For Health Care Workers HPA Tuberculosis Programme Board DRAFT FOR CONSULTATION October 2007 Interferon
More informationTargeted Testing for Tuberculosis Infection
Targeted Testing for Tuberculosis Infection CONTENTS Introduction... 3.2 Purpose... 3.2 Policy... 3.2 When to Conduct Targeted Testing... 3.3 Approaches to increasing targeted testing and treatment for
More informationUpdated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection United States, 2010
Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Recommendations and Reports June 25, 2010 / Vol. 59 / No. RR-5 Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium
More informationSan Francisco Guidelines on the Use of QuantiFERON-TB Gold (In Tube Method) for the Diagnosis of Latent TB Infection
San Francisco Guidelines on the Use of QuantiFERON-TB Gold (In Tube Method) for the Diagnosis of Latent TB Infection Rationale When to Screen for TB Choosing the Right TB Test Patient Registration Pre-Test
More informationChapter 3 Testing for Tuberculosis Infection and Disease
Chapter 3 Testing for Tuberculosis Infection and Disease Table of Contents Chapter Objectives.... 45 Introduction.... 47 Identifying High-Risk Groups for M. tuberculosis Testing... 47 Testing Methods for
More informationApril 22, 2015 Curry International Tuberculosis Center
Tools for TB Elimination: Early Case Finding and Prevention Determining Your High-Risk Groups: Using the Universal Risk Assessment Tool Wednesday, d Sacramento, California Mike Carson, MS Program Manager
More informationImpact of Diabetes on Treatment Outcomes among Maryland Tuberculosis Cases, 2004-2005. Tania Tang PHASE Symposium May 12, 2007
Impact of Diabetes on Treatment Outcomes among Maryland Tuberculosis Cases, 2004-2005 Tania Tang PHASE Symposium May 12, 2007 Presentation Outline Background Research Questions Methods Results Discussion
More informationTuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California
Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California 1 of 7 Table of Contents Preface 2 TB Symptoms and TB History 2 Initial Screening 2 Follow-Up Screening
More informationTuberculosis Contact Investigation in a Renal Dialysis Center: Blood Vs. Skin test
Tuberculosis Contact Investigation in a Renal Dialysis Center: Blood Vs. Skin test Kevin L. Winthrop M.D., M.P.H. Assistant Professor of Medicine Divisions of Infectious Diseases and Public Health and
More informationChildhood Tuberculosis Some Basic Issues. Jeffrey R. Starke, M.D. Baylor College of Medicine
Childhood Tuberculosis Some Basic Issues Jeffrey R. Starke, M.D. Baylor College of Medicine TUBERCULOSIS IS A SOCIAL DISEASE WITH MEDICAL IMPLICATIONS THE GREAT PARADOX OF TUBERCULOSIS A CAUTIONARY TALE
More informationSerial Testing for TB Infection with IGRAs: Understanding the Sources of Variability
Serial Testing for TB Infection with IGRAs: Understanding the Sources of Variability Niaz Banaei MD Assistant Professor of Pathology and Medicine Director, Fellowship in Global Health Diagnostics Director,
More informationJournal of Infectious Diseases Advance Access published January 26, 2015
Journal of Infectious Diseases Advance Access published January 26, 2015 1 Effect of immune status on serial QuantiFERON-TB Gold In-Tube LTBI screening in persons with HIV in a low TB incidence country
More informationATTACHMENT 2. New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS
ATTACHMENT 2 New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS 1. QUESTION Is it required to submit the Annual Report of TB Testing in Schools Form (TB-57) to the New Jersey
More informationQuality and Productivity Commission 26 th Annual Productivity and Quality Awards Program Investing in a Quality Future 2012 APPLICATION
DATE OF IMPLEMENTATION/ADOPTION: JUNE 1, 2011 (Must have been implemented at least one year - on or before June 30, 2011) PROJECT STATUS: X Ongoing One-time only DID YOU SUBMIT THIS PROJECT BEFORE? Yes
More informationHealth Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB)
Health Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB) Draft Interim HPA Guidance HPA Tuberculosis Programme Board Health Protection
More informationPediatric Latent TB Diagnosis and Treatment
Date Updated: April 2015 Guidelines Reviewed: 1. CDC Latent TB Guidelines 2. Harborview Pediatric Clinic Latent TB Management, 2010 3. Pediatric Associates Latent TB Guidelines, 2013 4. Seattle Children
More informationInterferon-gamma-release assays: Better than tuberculin skin testing?
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will use and interpret the new blood tests for tuberculosis correctly CYNDEE MIRANDA, MD Department of Infectious Disease, Medicine Institute, Cleveland
More informationFrequently Asked Questions
Frequently Asked Questions QuantiFERON -TB Gold Health Professionals www.quantiferon.com 2 FAQ - Health Professionals Table of contents About TB 6 What is latent TB? And how is it different from active
More informationTUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG
TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG Tx CENTERS Tuberculosis Control Program Health and Human Services Agency San Diego County INTRODUCTION Reducing TB disease requires
More informationPerils and Pitfalls in Clinical Trials of Diagnostic Tests for Tuberculosis. Richard O Brien, MD Foundation for Innovative New Diagnostics Geneva
Perils and Pitfalls in Clinical Trials of Diagnostic Tests for Tuberculosis Richard O Brien, MD Foundation for Innovative New Diagnostics Geneva 1 Outline of Presentation Statement of the problem Common
More informationJoint MSPAS/MPH Student Health and Immunization Clearance Requirements Effective October 2014
Joint MSPAS/MPH Student Health and Immunization Clearance Requirements Effective October 2014 Students must remain in compliance throughout enrollment within the program. Students who are not in compliance
More informationInterferon Gamma Release Assays (IGRAs) in the Diagnosis of Tuberculosis
Interferon Gamma Release Assays (IGRAs) in the Diagnosis of Tuberculosis Richard B. Clark, PhD, D(ABMM) Quest Diagnostics Nichols Institute Chantilly, VA Dale Schwab, PhD, D(ABMM) Quest Diagnostics Nichols
More informationDiagnosis of Tuberculosis Infection
Diagnosis of Tuberculosis Infection CONTENTS Introduction... 7.2 Purpose... 7.2 Policy... 7.2 High-Risk Groups... 7.3 Diagnosis of Tuberculosis Infection... 7.4 Interferon gamma release assays... 7.4 Mantoux
More informationHealth Careers and Nursing Immunization and Health Requirement Completion Guide
Health Careers and Nursing Immunization and Health Requirement Completion Guide Table of Contents OVERVIEW... 2 TITERS AND IMMUNIZATIONS... 2 MMR Titer (Measles, Mumps, Rubella)... 2 Varicella (Chicken
More informationGuidelines for Tuberculosis Screening of Healthcare Students in the greater Auckland region
Guidelines for Tuberculosis Screening of Healthcare Students in the greater Auckland region Auckland Regional Public Health Service 2013 Document Controller: Updated December 2013 Medical Officer of Health,
More informationLTBI Program Implementation in a Substance Abuse Treatment Facility
LTBI Program Implementation in a Substance Abuse Treatment Facility (A Case Study) Acknowledgments The New Jersey Medical School (NJMS) National Tuberculosis Center wishes to acknowledge the following
More informationRegulations for Tuberculosis Control in Minnesota Health Care Settings
Regulations for Tuberculosis Control in Minnesota Health Care Settings A guide for implementing tuberculosis (TB) infection control regulations in your facility Tuberculosis Prevention and Control Program
More informationRecent Advances in The Treatment of Mycobacterium Tuberculosis
Recent Advances in The Treatment of Mycobacterium Tuberculosis Dr Mohd Arif Mohd Zim Senior Lecturer & Respiratory Physician Faculty of Medicine, Universiti Teknologi MARA mohdarif035@salam.uitm.edu.my
More informationJoint MSPAS/MPH Student Health and Immunization Clearance Requirements Effective February 2016
Joint MSPAS/MPH Student Health and Immunization Clearance Requirements Effective February 2016 Students must remain in compliance throughout enrollment within the program. Students who are not in compliance
More informationGuidelines for Tuberculosis Control in New Zealand 2010 Chapter 8: Diagnosis and Treatment of Latent Tuberculosis Infection
Guidelines for Tuberculosis Control in New Zealand 2010 Chapter 8: Diagnosis and Treatment of Latent Tuberculosis Infection Ministry of Health. 2010. Guidelines for Tuberculosis Control in New Zealand
More informationALLIED HEALTH AND NURSING PROGRAM HEALTH REQUIREMENTS
IMMUNIZATIONS: Page 1 ALLIED HEALTH AND NURSING PROGRAM HEALTH REQUIREMENTS Measles 2 MMR Vaccinations 2 Measles Vaccinations Positive antibody titer for Measles (lab report required or employer health
More informationTuberculosis in Children and Adolescents
Tuberculosis in Children and Adolescents Ritu Banerjee, MD, Ph.D TB Clinical Intensive April 8, 2015 2014 MFMER slide-1 Disclosures None 2014 MFMER slide-2 Objectives Describe the epidemiology of pediatric
More informationANNOUNCEMENTS. Navy and Marine Corps Public Health Center 0
ANNOUNCEMENTS All participants must register for the Monthly Disease Surveillance Trainings in order for us to provide CMEs/CNEs: 1. Log-on or Request log-on ID/password: https://tiny.army.mil/r/zb8a/cme
More informationT tuberculin Skin Test (TST) and QFT-GIT in Military Personnel
2 COMPARISON OF MANTOUX AND QUANTIFERON-TB GOLD TEST FOR DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION IN ARMY PERSONNEL Willeke P.J. Franken 1, Joost F. Timmermans 2, Corine Prins 1, Evert-Jan H.J. Slootman
More informationMaria Dalbey RN. BSN, MA, MBA March 17 th, 2015
Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015 2 Objectives Participants will be able to : Understand the Pathogenesis of Tuberculosis (TB) Identify the Goals of Public Health for TB Identify Hierarchy
More informationAssisted Living - TB Risk Assessment
Montana DPHHS Tuberculosis Program Assisted Living - TB Risk Assessment Assisted Living, Adult Day Care, Adult Foster Care & Transitional Living Centers Today s Date Facility Address Phone County Completed
More informationTuberculosis Transmission in Households and Communities
Tuberculosis Transmission in Households and Communities Christopher C. Whalen, M.D., M.S. Department of Epidemiology and Biostatistics 2008, The University of Georgia. All rights reserved. Model for M.
More informationPRE-EMPLOYMENT SCREENING AND IMMUNIZATION DOCUMENTATION
Page 185 PRE-EMPLOYMENT SCREENING AND IMMUNIZATION DOCUMENTATION In order to protect the health of all residents/fellows, employees and patients, and in order to comply with CDC guidelines and immunization
More informationTuberculosis Case Management for Undocumented and Deportable Inmates/Prisoners/Detainees in Federal Custody
Background Federal Bureau of Prisons (BOP) Tuberculosis Case Management for Undocumented and Deportable Inmates/Prisoners/Detainees in Federal Custody Federal Bureau of Prisons (Department of Justice)
More informationTuberculosis in children in Europe -the ptbnet
Tuberculosis in children in Europe -the ptbnet Beate Kampmann FRCPCH PhD A/Professor in Paediatric Infection & Immunity Consultant Paediatrician Imperial College London, UK and Institute of Infectious
More informationMaryland County Health Department Tuberculosis Infection Control Plan
Maryland County Health Department Tuberculosis Infection Control Plan Introduction In 1998, the Division of TB Control developed a Tuberculosis (TB) Prevention Plan template for use by the local health
More informationMassachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention
Massachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention Screening Infants and Children for Tuberculosis in Massachusetts Executive Summary In Massachusetts,
More informationLong-term Care - TB Risk Assessment
Montana DPHHS Tuberculosis Program Long-term Care - TB Risk Assessment Long-term Care, Residential Treatment, ESRD (outpatient), Hospice (inpatient) Today s Date Facility Address Phone County Completed
More informationNotes. Complete childhood vaccination course (CCV) CCV and DTP booster as adolescent/adult within last 10 years
Student Immunisation Record School of Nursing, Midwifery and Social Work Section 1: Information for students enrolled in Nursing and Midwifery programs Students enrolled in programs offered by our School
More informationTuberculosis. Subject. Goal/Objective. Instructions. Rationale. Operations Directorate, Health Branch Immigration Medical Examination Instructions
Subject Instructions for the screening of clients to detect tuberculosis (TB) in the context of the Canadian immigration medical examination (IME). Goal/Objective These instructions are provided to ensure
More informationSummary. Request for Advice
Summary Health Council of the Netherlands. Vaccination of young children against tuberculosis. The Hague: Health Council of the Netherlands, 2011; publication no. 2011/04 Even though the global prevalence
More informationTuberculosis Exposure Control Plan for Low Risk Dental Offices
Tuberculosis Exposure Control Plan for Low Risk Dental Offices A. BACKGROUND According to the CDC, approximately one-third of the world s population, almost two billion people, are infected with tuberculosis.
More informationInjection Drug Users in Miami-Dade: NHBS-IDU2 Cycle Preliminary Results
Injection Drug Users in Miami-Dade: NHBS-IDU2 Cycle Preliminary Results David W. Forrest, Ph.D. Marlene LaLota, M.P.H. John-Mark Schacht Gabriel A. Cardenas, M.P.H. Lisa Metsch, Ph.D. National HIV Behavioral
More informationApril King-Todd 2014 National TB Conference Atlanta, Georgia June 10, 2014
An Outbreak of TB Among the Homeless: The Aftermath in a High Incidence County April King-Todd, RN, MPH Los Angeles County Department of Public Health Tuberculosis Control Program National TB Nurses Coalition
More informationOregon Coast Community College Medical Assistant Program Application 2015-2016 Academic Year Deadline: December 4, 2015
Oregon Coast Community College Medical Assistant Program Application 2015-2016 Academic Year Deadline: December 4, 2015 Program Description The Oregon Coast Community College Medical Assistant Program
More informationUse of Nucleic Acid Amplification Tests in TB patients in California 2010-2012
Use of Nucleic Acid Amplification Tests in TB patients in California 2010-2012 Lisa Pascopella, PhD, MPH Pennan Barry, MD, MPH Tuberculosis Control Branch, Division of Communicable Disease Control, Center
More informationA Ministry of the Archdiocese of Galveston-Houston A United Way Agency
A Ministry of the Archdiocese of Galveston-Houston A United Way Agency Integrated Multidsciplinary Approach to Adapt Routine HIV Screening in a Safety Net Clinic Setting Sherri D. Onyiego MD, PhD Baylor
More informationCTCA POSITION ON TB EXAMINATION OF SCHOOL EMPLOYEES AND VOLUNTEERS
CTCA POSITION ON TB EXAMINATION OF SCHOOL EMPLOYEES AND VOLUNTEERS Introduction Although progress has been made, tuberculosis (TB) continues to be a significant public health problem; appropriate TB examination
More informationInterim Guidance for Medical Schools on health checks for active and latent Tuberculosis in medical students returning from elective periods overseas
Interim Guidance for Medical Schools on health checks for active and latent Tuberculosis in medical students returning from elective periods overseas This document has been developed by: Dr Mathina Darmalingam
More informationTUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY. Stephanie N. Lin MD 2/12/2016
TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY Stephanie N. Lin MD 2/12/2016 Epidemiology of TB 9.6 million new cases in 2014 12% of them are in HIV positive patients 1.5 million deaths in 2014 ~646
More informationChallenges in Pediatric Tuberculosis. Mimi Emig, MD Spectrum Health Kent County Health Department
Challenges in Pediatric Tuberculosis Mimi Emig, MD Spectrum Health Kent County Health Department Pediatric Tuberculosis: A Missed Public Health Opportunity Mimi Emig, MD Spectrum Health Kent County Health
More informationScreening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults)
Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults) H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg
More informationCanadian Tuberculosis Standards
Canadian Tuberculosis Standards 7 th Edition Chapter 4: Diagnosis of Latent Tuberculosis Infection Canadian Tuberculosis Standards, 7 th Edition is available on Internet at the following address: www.phac-aspc.gc.ca
More informationTuberculosis infection in drug users: interferon-gamma release assay performance
INT J TUBERC LUNG DIS 11(11):1183 1189 2007 The Union Tuberculosis infection in drug users: interferon-gamma release assay performance C. Z. Grimes,* L-Y. Hwang,* M. L. Williams,* C. M. Austin, E. A. Graviss
More informationEXPANDED HIV TESTING AND LINKAGE TO CARE (X-TLC) IN HEALTHCARE SETTINGS ON THE SOUTH SIDE OF CHICAGO
EXPANDED HIV TESTING AND LINKAGE TO CARE (X-TLC) IN HEALTHCARE SETTINGS ON THE SOUTH SIDE OF CHICAGO R Eavou, M Taylor, C Bertozzi-Villa, D Amarathithada, R Buffington, D Pitrak and N Benbow HIV Prevention
More informationChallenges and Progress: Implementing HIV Screening in Health-Care Settings
Challenges and Progress: Implementing HIV Screening in Health-Care Settings Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV/AIDS,
More informationSuggested Reporting Language for the HIV Laboratory Diagnostic Testing Algorithm
Suggested Reporting Language for the HIV Laboratory Diagnostic Testing Algorithm November 2013 Introduction In March 2010, the Centers for Disease Control and Prevention (CDC) and the Association of Public
More informationPolicy Directive: compliance is mandatory
Policy Directive: compliance is mandatory Policy for Control of Tuberculosis in South Australian Health Services Policy developed by: Public Health and Clinical Coordination Approved at Portfolio Executive
More informationHow To Test For Latent Tuberculosis
IGRAs: What do they tell and what don t they tell us? 2 nd European Advanced Clinical Tuberculosis Course Monday 22 nd September 2014 Amsterdam, Netherlands Ibrahim Abubakar Professor of Infectious Disease
More informationPragmatic Seamless Design for Efficacy Trial of Asthma Management with reduced Cost. Mei Lu, PhD Christine Joseph, Ph.D
Pragmatic Seamless Design for Efficacy Trial of Asthma Management with reduced Cost Mei Lu, PhD Christine Joseph, Ph.D Henry Ford Health System May 19, 2013 Puff City Pragmatic RCT: Partners HFHS Clinical
More informationRole of Quantiferon-TB Gold Assays in Detecting Latent Tuberculous Infection among Contacts of Active Tuberculous Patients *
Med. J. Cairo Univ., Vol. 79, No. 1, June 169-175, 2011 www.medicaljournalofcairouniversity.com Role of Quantiferon-TB Gold Assays in Detecting Latent Tuberculous Infection among Contacts of Active Tuberculous
More informationRisk for Tuberculosis in Swiss Hospitals. Content. Introduction. Dr. med. Alexander Turk Zürcher Höhenklinik Wald alexander.turk@zhw.
Risk for Tuberculosis in Swiss Hospitals 17. Tuberkulose Symposium Münchenwiler Risk for Tuberculosis in Swiss Hospitals Dr. med. Alexander Turk Zürcher Höhenklinik Wald alexander.turk@zhw.ch 1 Content
More informationThe McGregor Clinic Inc. Patient Registration/Demographic Form. Patient Enrollment PLEASE USE LEGAL NAME
The McGregor Clinic Inc. Patient Registration/Demographic Form Patient Enrollment PLEASE USE LEGAL NAME First Name: MI: Last Name: of Birth: Sex: SS#: Marital Status: Single Married Separated Divorced
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationSan Francisco Treatment Guidelines for Latent Tuberculosis Infection
City and County of San Francisco Department of Public Health Tuberculosis Control Unit Julie Higashi, MD, PhD Director Population Health Division Edwin M. Lee Mayor Disease Prevention and Control Branch
More informationAmerican College Health Association (ACHA) TB Screening and Targeted Testing Recommendations Gregory Juckett, MD, MPH Professor of Family Medicine
American College Health Association (ACHA) TB Screening and Targeted Testing Recommendations Gregory Juckett, MD, MPH Professor of Family Medicine West Virginia University gjuckett@hsc.wvu.edu Objectives
More informationUniversity of Nebraska Medical Center, Department of Health Services Research and Administration, Omaha, NE
Research Mycobacterium Tuberculosis Infection, Immigration Status, and Diagnostic Discordance: A Comparison of Tuberculin Skin Test and QuantiFERON -TB Gold In-Tube Test Among Immigrants to the U.S. Fernando
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Tuberculosis Revised August 2015 Tuberculosis 1.0 Provincial Reporting Confirmed and suspect cases
More informationRefugees with diabetes mellitus have higher prevalence of latent tuberculosis infection
Refugees with diabetes mellitus have higher prevalence of latent tuberculosis infection Matthew Magee Division of Epidemiology and Biostatistics School of Public Health, Georgia State University Saturday,
More informationEmergency Medical Technician
Program Description Emergency Medical Technician The Emergency Medical Technician program provides instruction in delivering proper emergency care to the sick and injured in a pre-hospital setting. The
More informationTuberculosis Screening and Targeted Testing of College and University Students
APRIL 2014 ACHA Guidelines Tuberculosis Screening and Targeted Testing of College and University Students Purpose Screening and targeted testing for tuberculosis (TB) is a key strategy for controlling
More information09/27/2006 Centers for Disease Control and Prevention Division of Tuberculosis Elimination
Appendix B. Tuberculosis (TB) risk assessment worksheet This model worksheet should be considered for use in performing TB risk assessments for healthcare facilities and nontraditional facility-based settings.
More informationLatent Tuberculosis Infection: A Guide for Primary Health Care Providers
Latent Tuberculosis Infection: A Guide for Primary Health Care Providers A B Latent Tuberculosis Infection: A Guide for Primary Health Care Providers U.S. Department of Health and Human Services Centers
More informationClinical description 2 Laboratory test for diagnosis 3. Incubation period 4 Mode of transmission 4 Period of communicability 4
Tuberculosis Contents Epidemiology in New Zealand 2 Case definition 2 Clinical description 2 Laboratory test for diagnosis 3 Case classification 3 Spread of infection 4 Incubation period 4 Mode of transmission
More informationSPECIAL FEATURES: HEALTH POLICY
Public Health Nursing 0737-1209/ 2013 Wiley Periodicals, Inc. doi: 10.1111/phn.12083 SPECIAL FEATURES: HEALTH POLICY Cost-effectiveness of Using Quantiferon Gold (QFT-G) versus Tuberculin Skin Test (TST)
More informationAn Electronic Health Record Alert for Hepatitis C Screening of Baby Boomers in Primary Care: A Cluster Randomized Controlled Trial
An Electronic Health Record Alert for Hepatitis C Screening of Baby Boomers in Primary Care: A Cluster Randomized Controlled Trial K Krauskopf, N Kil, A Sofianou, W Toribio, J Lyons, M Singer, J Kannry,
More informationUsing HIV Surveillance Data to Calculate Measures for the Continuum of HIV Care
Using HIV Surveillance Data to Calculate Measures for the Continuum of HIV Care Anna Satcher Johnson, MPH Symposium on Measuring the HIV Care Continuum Center for AIDS Research University of Washington
More informationOncology Nursing Society Annual Progress Report: 2008 Formula Grant
Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The Oncology Nursing Society received $12,473 in formula funds for
More information2015 Michigan Department of Health and Human Services Adult Medicaid Health Plan CAHPS Report
2015 State of Michigan Department of Health and Human Services 2015 Michigan Department of Health and Human Services Adult Medicaid Health Plan CAHPS Report September 2015 Draft Draft 3133 East Camelback
More information3. Blood and blood products such as serum, plasma, and other blood components.
Mississippi Downloaded 01/2011 101.11 Infectious Medical Waste. The term "infectious medical waste" includes solid or liquid wastes which may contain pathogens with sufficient virulence and quantity such
More informationQuantiFERON TB Gold In Tube Method (QGIT Test) Manufacturer: Cellestis Inc. (USA) a QIAGEN Company
QuantiFERON TB Gold In Tube Method (QGIT Test) Manufacturer: Cellestis Inc. (USA) a QIAGEN Company P1078 TB APPRISE TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed
More informationHEALTH INSURANCE ENROLLMENT FORM
HEALTH INSURANCE ENROLLMENT FORM Requirements You must complete the Enrollment Form as part of the New Hire Process. You must elect or decline coverage on the Enrollment Form. Return the Enrollment Form
More informationAbstract. 1. Basic underlying view
_ Abstract 1. Basic underlying view Mycobacterium tuberculosis Table 1 2. LTBI treatment subjects 1. Basic view 2. TB development risk factors and infection diagnosis i. HIV/AIDS ii. Hemodialysis for
More informationT()LED() Name ofpolicy: Mandatory Tuberculosis (TB) Screening of Students from World Health Organization Designated High TB Prevalence Countries
Name ofpolicy: Mandatory Tuberculosis (TB) Screening of Students from World Health Organization Designated High TB Prevalence Countries Policy Number: 3364-81-04-030 T()LED() Revision date: I 0/22/13 Approving
More informationOpportunistic Infections Related to Immune Suppressant and Biologic Drug Therapy in IBD
Opportunistic Infections Related to Immune Suppressant and Biologic Drug Therapy in IBD Raymond Cross, M.D., M.S., AGAF Associate Professor of Medicine Director of the Inflammatory Bowel Disease Program
More informationPrison and Jail Health January 18, 2007. Viewer Call-In. Evaluations. www.t2b2.org. Phone: 800-452-0662 Fax: 518-426-0696. 518-402-0330 www.t2b2.
Prison and Jail Health January 18, 2007 Guthrie S. Birkhead, M.D., M.P.H Director, AIDS Institute and Center for Community Health New York State Department of Health (NYSDOH) Lester N. Wright, M.D., M.P.H.
More information